Phase I Services

Charles River conducts the full range of human pharmacology studies with the objective of assessing tolerability, defining/describing pharmacokinetic and pharmacodynamic parameters, and exploring drug metabolism and drug interactions. Our clients benefit from the quality of our services and operating standards as we help them achieve and exceed their goals.

With the recent acquisition of Northwest Kinetics, we established a Phase I Clinical Services presence in North America, which in conjunction with our facility in Edinburgh, Scotland, positions us exceptionally well to support our clients’ high-end clinical pharmacology studies. Between the two state-of-the-art facilities, our capabilities encompass:  

• Over 300 beds, plus dedicated wards for radio-labeled studies
• 100-110 studies each year (approximately ten are first-in-man)
• High ratio of medical staff to volunteers
• 24/7 nursing support and dedicated MDs
• Dedicated manufacturing unit and sample processing laboratory
• Close proximity to our Central Laboratory, Bioanalytical, and Pharmacokinetic services
• Digital ECG capture and continuous telemetry capabilities
• Access to Independent Ethics Committee (IRB)
• Database of more than 70,000 healthy volunteers
• Control of environmental conditions as well as subject activity, safety and security
• Evaluation of pharmacodynamic effects
• Support from Data Managers, Biostatisticians, and Medical Writers with exceptional experience in Phase I studies

What's New

Charles River Laboratories Clinical Services -- Northwest Kinetics Achieves Mortara Certified Partner Status

Charles River Acquires Northwest Kinetics

All news items

 Charles River Home | Careers | Humane Care | Events | News Room | Investor Relations | Site Index | Contact